Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6432924 | 1.00 | HCAR2 (0.34) | HCAR2ALDH1A1GAA | |
| SCHEMBL6432921 | 1.00 | HCAR2 (0.34) | HCAR2ALDH1A1GAA | |
| SCHEMBL6432413 | 0.82 | HCAR2 (0.40) | HCAR2 | |
| SCHEMBL6432420 | 0.82 | HCAR2 (0.40) | HCAR2 | |
| SCHEMBL6432409 | 0.82 | HCAR2 (0.40) | HCAR2 | |
| SCHEMBL1066500 | 0.77 | HCAR2 (0.34) | HCAR2ALDH1A1GAA | |
| SCHEMBL10879059 | 0.74 | NPSR1 (0.46) | HCAR2ALDH1A1GAA | |
| SCHEMBL10879052 | 0.74 | NPSR1 (0.46) | HCAR2ALDH1A1GAA | |
| SCHEMBL11482890 | 0.72 | — | — | |
| SCHEMBL7975075 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282619-B1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | claimed |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2004-02-05 | — | — | US | claimed |
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2003-05-15 | — | — | US | claimed |
| EP-1282619-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | claimed |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | HOFFMANN-LA ROCHE INC. | 2001-12-06 | — | — | US | claimed |
| WO-2001079202-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-25 | — | — | WO | claimed |
| EP-1282619-B1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2005-06-22 | — | — | EP | disclosed |
| US-6753432-B2 | BROMOMETHYLATION OR CHLOROMETHYLATION; CONDENSATION WITH PRIMARY AMIDE; DEESTERIFICATION, SULFONATION | HOFFMANN-LA ROCHE INC. | 2004-06-22 | — | — | US | disclosed |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2004-02-05 | — | — | US | disclosed |
| US-6620941-B2 | Bromination of ethyl 3-oxovalerate, condensing with benzamide, then reducing with diisobutylaluminum hydride and sulfonating to form 2-(5-Methyl-2- phenyl-4-oxazolyl)ethanomethanesulfonic ester, used as chemical intermediates | HOFFMANN-LA ROCHE INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SCALONE MICHELANGELO (CH) | 2003-05-15 | — | — | US | disclosed |
| US-6531609-B2 | Bromomethylation or chloromethylation of a 1-benzothiophene-4-oxyethyl-oxazole derivative to from intermediate, reacting the intermediate with 2,4-thiazolidinedione | HOFFMANN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| EP-1282619-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | HOFFMANN-LA ROCHE INC. | 2001-12-06 | — | — | US | disclosed |
| WO-2001079202-A1 | PROCESSES FOR THE PREPARATION OF THIAZOLIDINEDIONE DERIVATIVES AND INTERMEDIATES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092916-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | HCAR2 1717/4885ALDH1A1 130/4885GAA 1358/4885 |
| US-20010049445-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | HCAR2 1717/4885ALDH1A1 130/4885GAA 1358/4885 |
| US-20040024222-A1 | Process for the preparation of thiazolidinedione derivatives | SLC5A2, CYP4B1, CYP4F3 | HCAR2 1717/4885ALDH1A1 130/4885GAA 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.